Massive Transcranial Parotid Pleomorphic Adenoma: Recurrence after 30 Years^[*]

Abstract

Pleomorphic adenoma, also known as benign mixed tumor, is the most common tumor affecting the parotid gland and can reach massive size; however, intracranial invasion is rare. Recurrence of pleomorphic adenoma after excision is a well-known phenomenon and can present decades after resection of the primary tumor. Here we present the case of a 53-year-old man who presented to our clinic with ear fullness, otalgia, and hearing loss 30 years after undergoing total parotidectomy and external beam radiotherapy for pleomorphic adenoma. Magnetic resonance imaging revealed a massive transcranial tumor invading the mastoid cavity, the dura of the posterior fossa, the fallopian and semicircular canals, the jugular foramen, the lateral infratemporal fossa skull base, the sigmoid and transverse sinuses, and the superior parapharyngeal region. Gross examination and histopathological studies confirmed that the mass was a recurrent pleomorphic adenoma. Here we discuss the features of recurrent pleomorphic adenoma and review the current literature.

Keywords

pleomorphic adenoma - benign mixed tumor - recurrent pleomorphic adenoma - carcinoma ex pleomorphic adenoma - intracranial invasion

^* This article was originally published in Skull Base Reports on November 21, 2011 (DOI: 10.1055/s-0031-1296032)

• References

• 1 Lingam RK, Daghir AA, Nigar E, Abbas SA, Kumar M. Pleomorphic adenoma (benign mixed tumour) of the salivary glands: its diverse clinical, radiological, and histopathological presentation. Br J Oral Maxillofac Surg 2011; 49 (1) 14-20
• 2 O’Brien CJ. Current management of benign parotid tumors—the role of limited superficial parotidectomy. Head Neck 2003; 25 (11) 946-952
• 3 Piekarski J, Nejc D, Szymczak W, Wronski K, Jeziorski A. Results of extracapsular dissection of pleomorphic adenoma of parotid gland. J Oral Maxillofac Surg 2004; 62 (10) 1198-1202
• 4 Subhashraj K. Salivary gland tumors: a single institution experience in India. Br J Oral Maxillofac Surg 2008; 46 (8) 635-638
• 5 Laccourreye H, Laccourreye O, Cauchois R, Jouffre V, Ménard M, Brasnu D. Total conservative parotidectomy for primary benign pleomorphic adenoma of the parotid gland: a 25-year experience with 229 patients. Laryngoscope 1994; 104 (12) 1487-1494
• 6 Witt RL. The significance of the margin in parotid surgery for pleomorphic adenoma. Laryngoscope 2002; 112 (12) 2141-2154
• 7 Bentz BG, Hughes CA, Lüdemann JP, Maddalozzo J. Masses of the salivary gland region in children. Arch Otolaryngol Head Neck Surg 2000; 126 (12) 1435-1439
• 8 Luna MA, Batsakis JG, el-Naggar AK. Salivary gland tumors in children. Ann Otol Rhinol Laryngol 1991; 100 (10) 869-871
• 9 Linares CZ. Mixed tumor of parotid in childhood. Int J Pediatr Otorhinolaryngol 1991; 22 (3) 269-273
• 10 Yasumoto M, Sunaba K, Shibuya H, Kurabayashi T. Recurrent pleomorphic adenoma of the head and neck. Neuroradiology 1999; 41 (4) 300-304
• 11 Koral K, Sayre J, Bhuta S, Abemayor E, Lufkin R. Recurrent pleomorphic adenoma of the parotid gland in pediatric and adult patients: value of multiple lesions as a diagnostic indicator. AJR Am J Roentgenol 2003; 180 (4) 1171-1174
• 12 Suh MW, Hah JH, Kwon SK , et al. Clinical manifestations of recurrent parotid pleomorphic adenoma. Clin Exp Otorhinolaryngol 2009; 2 (4) 193-197
• 13 Orita Y, Hamaya K, Miki K , et al. Satellite tumors surrounding primary pleomorphic adenomas of the parotid gland. Eur Arch Otorhinolaryngol 2010; 267 (5) 801-806
• 14 Azuma M, Kasai Y, Tamatani T, Sato M. Involvement of p53 mutation in the development of human salivary gland pleomorphic adenomas. Cancer Lett 1992; 65 (1) 61-71
• 15 Li X, Tsuji T, Wen S, Mimura Y, Sasaki K, Shinozaki F. Detection of numeric abnormalities of chromosome 17 and p53 deletions by fluorescence in situ hybridization in pleomorphic adenomas and carcinomas in pleomorphic adenoma. Correlation with p53 expression. Cancer 1997; 79 (12) 2314-2319
• 16 Tashiro T, Hirokawa M, Harada H, Yokoyama S, Sano T. Cell membrane expression of MIB-1 in salivary gland pleomorphic adenoma. Histopathology 2002; 41 (6) 559-561
• 17 Lazzaro B, Cleveland D. P53 and Ki-67 antigen expression in small oral biopsy specimens of salivary gland tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 89 (5) 613-617
• 18 Stennert E, Wittekindt C, Klussmann JP, Arnold G, Guntinas-Lichius O. Recurrent pleomorphic adenoma of the parotid gland: a prospective histopathological and immunohistochemical study. Laryngoscope 2004; 114 (1) 158-163
• 19 Hu XF, Yang E, Li J, Xing PX. MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma. Expert Rev Anticancer Ther 2006; 6 (8) 1261-1271
• 20 Hamada T, Matsukita S, Goto M , et al. Mucin expression in pleomorphic adenoma of salivary gland: a potential role for MUC1 as a marker to predict recurrence. J Clin Pathol 2004; 57 (8) 813-821
• 21 DeRoche TC, Hoschar AP, Hunt JL. Immunohistochemical evaluation of androgen receptor, HER-2/neu, and p53 in benign pleomorphic adenomas. Arch Pathol Lab Med 2008; 132 (12) 1907-1911
• 22 Al-Rawi NH, Omer H, Al Kawas S. Immunohistochemical analysis of P(53) and bcl-2 in benign and malignant salivary glands tumors. J Oral Pathol Med 2010; 39 (1) 48-55
• 23 Gedlicka C, Item CB, Wögerbauer M , et al. Transformation of pleomorphic adenoma to carcinoma ex pleomorphic adenoma of the parotid gland is independent of p53 mutations. J Surg Oncol 2010; 101 (2) 127-130
• 24 Luukkaa H, Klemi P, Leivo I, Vahlberg T, Grénman R. Prognostic significance of Ki-67 and p53 as tumor markers in salivary gland malignancies in Finland: an evaluation of 212 cases. Acta Oncol 2006; 45 (6) 669-675
• 25 Kamida T, Abe T, Inoue R, Kobayashi H, Suzuki M, Matsumoto A. Stereotactic radiosurgery for recurrent pleomorphic adenoma invading the skull base—case report—. Neurol Med Chir (Tokyo) 2005; 45 (3) 161-163